Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 2:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 4,699 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Administration of oral Placebo Clear all
Terminated Phase 2 Interventional Results available

Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction

NCT00802893
View directory record Official record
Conditions
Isolated Systolic Hypertension, Endothelial Dysfunction
Interventions
6R-BH4, Placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 6, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects

NCT03092102
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
HEC585
Drug
Lead sponsor
Sunshine Lake Pharma Co., Ltd.
Industry
Eligibility
18 Years to 60 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 6, 2026, 2:37 PM EDT
Completed Phase 4 Interventional Results available

PO vs. IV Acetaminophen Given Perioperatively for 24 hr Post-op Pain Control Following Total Hip or Knee Replacement

NCT02244619
View directory record Official record
Conditions
Post-op Pain
Interventions
Oral acetaminophen, IV acetaminophen
Drug
Lead sponsor
Kettering Health Network
Other
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 6, 2026, 2:37 PM EDT
Terminated Phase 2 Interventional Results available

STAT-STatin and Aspirin in Trauma

NCT02901067
View directory record Official record
Conditions
Wounds and Injuries, Venous Thromboembolism
Interventions
Aspirin and Rosuvastatin, Placebo (for Aspirin and Rosuvastatin)
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 6, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects

NCT02807207
View directory record Official record
Conditions
Healthy Subjects
Interventions
A: pacritinib, B: Placebo, C: moxifloxacin
Drug · Other
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 6, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Results available

Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)

NCT04187144
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Gepotidacin, Placebo matching nitrofurantoin, Nitrofurantoin, Placebo matching gepotidacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older · Female only
Enrollment
1,606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
79
States / cities
Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 66 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 6, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism

NCT00633893
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
2,711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
87
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 6, 2026, 2:37 PM EDT
Terminated Phase 2 Interventional Results available

Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers

NCT01217814
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, Placebo, Golimumab, methotrexate (MTX), Folic/folinic acid
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Freehold, New Jersey • New York, New York • Jackson, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Oct 6, 2026, 2:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia

NCT02104752
View directory record Official record
Conditions
Schizophrenia, Cognition, Psychosis
Interventions
Curcumin, Placebo
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 6, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)

NCT05660538
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Suzetrigine, Pregabalin, Placebo (matched to SUZ), Placebo (matched to pregabalin)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
50
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 6, 2026, 2:37 PM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Pyridostigmine Efficacy and Safety for Treatment of Ileus After Colorectal Surgery

NCT05334485
View directory record Official record
Conditions
Postoperative Ileus
Interventions
Pyridostigmine Bromide, Placebo
Drug · Other
Lead sponsor
Stefan Holubar MD MS FACS, FASCRS
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 6, 2026, 2:37 PM EDT
Completed Phase 2 Interventional

Dose-effect of SSR180575 in Diabetic Neuropathy

NCT00502515
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
SSR180575, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 6, 2026, 2:37 PM EDT
Completed Phase 2 Interventional

Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM (M2.0)

NCT01888835
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Mirtazapine, Placebo
Drug
Lead sponsor
Phillip Coffin, MD, MIA
Government
Eligibility
18 Years to 69 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 6, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Esomeprazole in Patients With Frequent Heartburn

NCT01370525
View directory record Official record
Conditions
Heartburn
Interventions
Esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
Sacramento, California • Seminole, Florida • Meridian, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 6, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Results available

A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone

NCT00295633
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Saxagliptin, Placebo, pioglitazone, rosiglitazone, metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
79
States / cities
Haleyville, Alabama • Mobile, Alabama • Ozark, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 6, 2026, 2:37 PM EDT
Completed Not applicable Interventional Results available

Trial of Acupuncture for Radiation-Induced Xerostomia in Head and Neck Cancer

NCT02589938
View directory record Official record
Conditions
Radiation-Induced Xerostomia, Head and Neck Cancer, Radiation Toxicity, Oral Complications of Chemotherapy and Head/Neck Radiation
Interventions
Standard Oral Hygiene, Standard Oral Hygiene + True Acupuncture, Standard Oral Hygiene + Sham Acupuncture
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
36
States / cities
Burbank, California • San Francisco, California • San Jose, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 6, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Blood Flow and Vascular Function in Cystic Fibrosis

NCT02057458
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Sildenafil (Acute-1 hour), Sildenafil (Subchronic-4 weeks), Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 6, 2026, 2:37 PM EDT
Completed Early Phase 1 Interventional

SDF Application in Oral Cancer Patients to Prevent Dental Caries

NCT05403125
View directory record Official record
Conditions
Dental Caries
Interventions
silver diamine fluoride, 38%, Sodium fluoride gel, 5000 PPM
Device
Lead sponsor
Texas A & M University Baylor College Of Dentistry
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 6, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients

NCT00466440
View directory record Official record
Conditions
Prostate Cancer
Interventions
enzastaurin, placebo, docetaxel, prednisone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
22
States / cities
Fullerton, California • Los Angeles, California • Northridge, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 6, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

DPP4 Inhibition & Beta Cell Function

NCT02683187
View directory record Official record
Conditions
Healthy
Interventions
Active Comparator: Sitagliptin, Placebo Comparator - No Sitagliptin
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
35 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 6, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus

NCT02175121
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Placebo, PF-06291874
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
19
States / cities
Anaheim, California • Chula Vista, California • Walnut Creek, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2016 · Synced Oct 6, 2026, 2:37 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis (SPMS)
Interventions
Remibrutinib (blinded), Placebo, Remibrutinib (Open label)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 6, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004)

NCT06625840
View directory record Official record
Conditions
Healthy
Interventions
MK-1167, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
60 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 6, 2026, 2:37 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A First Time in Man Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1979 in Healthy Males

NCT02072993
View directory record Official record
Conditions
Healthy Subjects
Interventions
AZD1979, Placebo to match
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Oct 6, 2026, 2:37 PM EDT